Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2021Author
Aydın, S. G.Kutlu, Yasin
Açıkgöz, Özgür
Bilici, A.
Hamdard, Jamshid
Ölmez, Ömer Fatih
Yıldız, Özcan
Metadata
Show full item recordCitation
Aydın, S. G., Kutlu, Y., Açıkgöz, Ö., Bilici, A., Hamdard, J., Ölmez, Ö. F. ... Yıldız, Ö. (2021). Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer. Journal of Thoracic Oncology içinde (S1078-S1079. ss.).Abstract
Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy alone,in second line setting atezolizumab or nivolumab are appropriate option regardless of PD -L1 expression.Herein we aimed to evaluate the efficacy and safety of immunotherapy for the second and later line settings in metastatic NSCLC.
WoS Q Kategorisi
Q1Source
Journal of Thoracic OncologyVolume
16Issue
10Collections
- Bildiri Koleksiyonu [515]
- WoS İndeksli Yayınlar Koleksiyonu [6465]